Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis says more cuts coming for New York Diovan plant

Novartis has notified the state of New York of its 83-employee layoff beginning Dec. 31 at its plant in Suffern, NY, a facility that will close in 2016, at which point essentially all traces of it will be eliminated.

Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche

So much for home field advantage. Switzerland plans to put the squeeze on drug prices, despite its corporate citizens Roche and Novartis. And the Basel-based companies are none too happy about the idea.

Wearables project aims to provide new source of data for MS trials

The study aims to recruit 40 people in the United Kingdom to wear watch-sized sensors on their belts. By placing the sensors around the body's center of mass the team from Imperial College London hope to gather data on each individual's position and walking speed.

Novartis commits $20M to build a new CAR-T development center at Penn

Novartis is contributing $20 million to build a new, 30,000-square-foot research center at Penn that will concentrate on developing a wave of new immuno-oncology drugs.

Ophthotech wins a $50M milestone from Novartis

Ophthotech says it won a $50 million enrollment milestone from Novartis for reaching a goal on its Phase III Fovista study for wet, age-related macular degeneration.

Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system

After initially leaving Novartis' meningitis B jab, Bexsero, off its national immunization program, the British government is now negotiating with the Swiss pharma over price--a series of events that's led a top Novartis Vaccines employee to tab the U.K. vaccination assessment system "flawed."

Novartis ready to start its engines for 'most exciting launch' in company history

Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696.

Novartis sees 'most exciting launch' ever with megablockbuster-to-be heart drug

Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696.

Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma giant painted in the numbers, completing the late-stage picture for a closely watched therapy that has the potential to rival the most successful drug franchises now on the market.

Mylan, Momenta, Sandoz join assault on Teva's new-and-improved Copaxone

After trying nearly everything in its power to protect lead product Copaxone from early generic competition, Teva just received some news it least wants to hear: Copycats are going after its new, long-acting version of the drug, too.